Clinical Cancer Research · 2020 · 15 citations · 40 references
Life SciencesMolecular BiologyPharmacologyImmunotherapyProtein TranslationProteomicsCancer ImmunotherapyCancer ProteomicsImmunomodulatory DrugsMultiple MyelomaProtein SynthesisTranslational BiomarkersImmunomodulatory EffectsMultiple Myeloma TherapyMultiple Myeloma TreatmentMyeloma Cell LinesProteasome Inhibitor TherapyProtein Expression LevelsProtein Translation ControlProteomic Data Analysis
Abstract Purpose: The prognosis of patients with multiple myeloma who are resistant to proteasome inhibitors, immunomodulatory drugs (IMiD), and daratumumab is extremely poor. Even B-cell maturation antigen–specific chimeric antigen receptor T-cell therapies provide only a temporary benefit before patients succumb to their disease. In this article, we interrogate the unique sensitivity of multiple myeloma cells to the alternative strategy of blocking protein translation with omacetaxine. Experimental Design: We determined protein translation levels (n = 17) and sensitivity to omacetaxine (n = 51) of primary multiple myeloma patient samples. Synergy was evaluated between omacetaxine and IMiDs in vitro, ex vivo, and in vivo. Underlying mechanism was investigated via proteomic analysis. Results: Almost universally, primary patient multiple myeloma cells exhibit >2.5-fold increased rates of protein translation compared with normal marrow cells. Ex vivo treatment with omacetaxine resulted in >50% reduction in viable multiple myeloma cells. In this cohort, high levels of translation serve as a biomarker for patient multiple myeloma cell sensitivity to omacetaxine. Unexpectedly, omacetaxine demonstrated synergy with IMiDs in multiple myeloma cell lines in vitro. In addition, in an IMiD-resistant relapsed patient sample, omacetaxine/IMiD combination treatment resensitized the multiple myeloma cells to the IMiD. Proteomic analysis found that the omacetaxine/IMiD combination treatment produced a double-hit on the IRF4/c-MYC pathway, which is critical to multiple myeloma survival. Conclusions: Overall, protein translation inhibitors represent a potential new drug class for myeloma treatment and provide a rationale for conducting clinical trials with omacetaxine alone and in combination with IMiDs for patients with relapsed/refractory multiple myeloma.
40
Universal sample preparation method for proteome analysis
Jacek R. Wiśniewski, Alexandre Zougman, Nagarjuna Nagaraj et al. · Nature Methods · 2009 · 8.7K citations
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Krönke, Namrata D. Udeshi, Anupama Narla et al. · Science · 2013 · 1.8K citations · Full text
Medicine, Cell Biology, Oncology +14
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu, Richard E. Middleton, Huahang Sun et al. · Science · 2013 · 1.6K citations · Full text
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy, Zoltán Szlávik, James B. Murray et al. · Nature · 2016 · 1.1K citations
Medicine, Oncology, Pharmacology +11